Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, announces it has acquired a majority interest in Aurion Biotech, Inc., a clinical-stage company developing advanced cell therapies to treat eye diseases. Aurion will operate as a separate company with full support from Alcon to advance its clinical-stage allogeneic cell therapy asset, AURN001, into Phase 3 for corneal edema secondary to corneal endothelial disease during the second half of 2025. Aurion will have access to the broader R&D, regulatory, medical ophthalmic and commercial capabilities of Alcon.
Read the full article: Alcon Acquires Majority Interest in Aurion Biotech, Inc. to Advance Innovative Cell Therapy for Corneal Endothelial Disease //
Source: https://www.businesswire.com/news/home/20250326174215/en/Alcon-Acquires-Majority-Interest-in-Aurion-Biotech-Inc.-to-Advance-Innovative-Cell-Therapy-for-Corneal-Endothelial-Disease